FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Roetzel is proud to announce that Michael Keller has been appointed to the Healthcare Scientific Advisory Board of Noble Financial Capital Markets (Noble).
“provide Noble and its clients with highly focused, in-depth, and substantive advice with regards to new developments and discoveries in the healthcare and medical industries”
Noble announced that the Scientific Advisory Board (SAB) will “provide Noble and its clients with highly focused, in-depth, and substantive advice with regards to new developments and discoveries in the healthcare and medical industries,” and sees the SAB as a logical extension of Noble’s services to investment and merchant bankers and corporate advisory clients.
Mr. Keller, a Partner in the firm’s Intellectual Property group, will bring to the SAB his extensive, 20-year experience in the fields of patent prosecution, counseling and licensing of therapeutic, diagnostic, pharmaceutical and medical device products, as well as his expertise in the negotiation of complex, product acquisition agreements.
Mr. Keller received both his B.S. and J.D. degrees from the University of Georgia and is a Ph.D. candidate in Biology at George Washington University. He is licensed to practice before the U.S. Patent and Trademark Office and in the states of Florida and Georgia.
Roetzel is a full-service law firm that provides comprehensive, integrated legal counsel to national and international clients. For more information, visit ralaw.com.